pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›minoxidil ER
drug · small molecule
save

minoxidil ER

Phase 3updated 6mo ago
by $MANE Veradermics, Inc🔗 ChEMBL
Phase 3
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval180 co-mentions · 40 sources
  • drugminoxidil91 co-mentions · 41 sources
  • companyBioClever 2005 SL1 co-mentions · 1 sources
  • tagDermatology1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for hypertension and hypotrichosis and 5 investigational indications.

targets

Sulfonylurea receptor 2, Kir6.2

all catalysts(0)

nothing on the calendar yet

Trials studying minoxidil ER

  • phase3Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopeciacompletedn=296
  • phase3Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopeciaactive not recruitingn=520
  • N/AEffects of a Topical Serum Solution on Hair Characteristicsactive not recruitingn=190
  • phase3Efficacy & Safety of Minoxidil SL Tablets in Men With AGAactive not recruitingn=132
  • phase3Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.not yet recruitingn=372
  • phase3Androgenic Alopecia TH07 Clinical Trialrecruitingn=420
  • phase2Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopeciacompletedn=110
  • phase3Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopeciarecruitingn=190

News(10)

  • Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
    China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up anot…
    biospace · 29d ago
  • Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
    Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold a second review voucher.
    biopharma_dive · 1mo ago
  • Veradermics’ minoxidil pill improves hair coverage in men in Phase 3
    In the wake of a successful IPO and strong stock growth throughout the year, Veradermics now has late-stage data to support a regulatory package for its hair loss pill.
    biospace · 1mo ago
  • Veradermics' oral Rogaine wins again at growing hair in late-stage trial
    Veradermics is taking another victory lap with its oral twist on minoxidil, commonly known as Rogaine. The Connecticut biotech said VDPHL01, its extended-release version of the decades-old hair-reg…
    endpoints · 1mo ago
  • Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss
    The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female pattern hair loss.
    biopharma_dive · 4mo ago
  • STAT+: Celcuity’s breast cancer drug approved, its first
    FDA's new CBER chief promises normalcy, an weight loss drug without GLP-1s, and more biotech news from The Readout
    stat · 4mo ago
  • Veradermics declares first efficacy win in women for hair loss drug
    Veradermics is for the first time reporting positive efficacy of its oral formulation of minoxidil in female pattern hair loss, which broadens the market potential of its flagship asset. In a mid-s…
    endpoints · 4mo ago
  • Veradermics soars on positive data for baldness treatment
    The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medica…
    biopharma_dive · 6mo ago
  • STAT+: Astellas retries XLMTM gene therapy after deaths
    Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
    stat · 6mo ago
  • Veradermics wins at growing hair with oral Rogaine in first key test as a public company
    Veradermics has succeeded in its first major test as a newly-minted public company. The biotech's form of oral Rogaine cleared the bar in a Phase 2/3 trial in men with mild-to-moderate pattern hair…
    endpoints · 6mo ago
view all news mentions →
trade names
Loniten, Lonolox, Men's rogaine, Minodyl, Minoxidil, Minoxidil (for men)
generic
minoxidil
MOA
Sulfonylurea receptor 2, Kir6.2 opener
indication
Androgenic Alopecia
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 6h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?